Essential thrombocythemia transformed to acute myelogenous leukemia with t(3;17)(p24; q12), del(5)(q13q34) after treatment with carboquone and hydroxyurea.
In 1991, a 52-year-old woman was diagnosed as having essential thrombocythemia (ET). She was doing well with continuous medication with carboquone (CQ) and subsequently hydroxyurea (HU). However, substantial leukocytosis with leukemic blast cells, anemia and thrombocytopenia developed in 1996. Analysis of peripheral blood showed 4.4 x 10(3)/microl white blood cells with 82% of leukemic blast cells. These blasts showed negative staining with myeloperoxidase by immunostaining, but the myeloperoxidase was positive by electron microscopic analysis. Cytogenetic analysis of bone marrow cells revealed a t(3;17)(p24; q12), del(5)(q13q34). On the basis of these findings, the leukemic blast cells were classified as acute myelogenous leukemia (AML:M0) in the FAB classification. The causative agent, CQ and HU in secondary leukemia from ET and chromosomal abnormality related to ET blastic crisis (BC) are discussed.
Tabata
M
M
Department of Hematology, Jichi Medical School, Tochigi, Japan.
Imagawa
S
S
Tarumoto
T
T
Ohmine
K
K
Hatake
K
K
Miura
Y
Y
Ozawa
K
K
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001752:Blast Crisis / Q000473:pathology*; D002225:Carbazilquinone / Q000008:administration & dosage; D002886:Chromosomes, Human, Pair 17; D002893:Chromosomes, Human, Pair 3; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000473:pathology*; D008875:Middle Aged; D013920:Thrombocythemia, Essential / Q000188:drug therapy / Q000473:pathology*
D002225:Carbazilquinone; D006918:Hydroxyurea